Search Result

Results for "

liver fatty acid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apical Sodium-Dependent Bile Acid Transporter (1) Fatty Acid Synthase (FASN) (1) G protein-coupled Bile Acid Receptor 1 (1) LXR (1) 17β-HSD (37) Acetyl-CoA Carboxylase (2) Acyltransferase (1) Adiponectin Receptor (1) Adrenergic Receptor (1) Akt (1) AMPK (6) AP-1 (1) Autophagy (1) Bacterial (1) Calcium Channel (1) Cannabinoid Receptor (1) Caspase (1) Dihydroorotate Dehydrogenase (2) Endogenous Metabolite (9) FGFR (1) FXR (4) GCGR (2) GLP Receptor (1) iGluR (1) Insulin Receptor (1) Interleukin Related (2) Isotope-Labeled Compounds (1) JNK (1) MDM-2/p53 (1) mTOR (1) Na+/K+ ATPase (1) NF-κB (3) NOD-like Receptor (NLR) (1) P2X Receptor (1) PPAR (6) Pyroptosis (1) Stearoyl-CoA Desaturase (SCD) (1) TGF-β Receptor (2) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (9) Infection (6) Inflammation/Immunology (17) Metabolic Disease (77) Neurological Disease (1)

By Targets:

Apical Sodium-Dependent Bile Acid Transporter (1)

Fatty Acid Synthase (FASN) (1)

G protein-coupled Bile Acid Receptor 1 (1)

LXR (1)

17β-HSD (37)

Acetyl-CoA Carboxylase (2)

Acyltransferase (1)

Adiponectin Receptor (1)

Adrenergic Receptor (1)

Akt (1)

AMPK (6)

AP-1 (1)

Autophagy (1)

Bacterial (1)

Calcium Channel (1)

Cannabinoid Receptor (1)

Caspase (1)

Dihydroorotate Dehydrogenase (2)

Endogenous Metabolite (9)

FGFR (1)

FXR (4)

GCGR (2)

GLP Receptor (1)

iGluR (1)

Insulin Receptor (1)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

JNK (1)

MDM-2/p53 (1)

mTOR (1)

Na+/K+ ATPase (1)

NF-κB (3)

NOD-like Receptor (NLR) (1)

P2X Receptor (1)

PPAR (6)

Pyroptosis (1)

Stearoyl-CoA Desaturase (SCD) (1)

TGF-β Receptor (2)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (5)

Cardiovascular Disease (9)

Infection (6)

Inflammation/Immunology (17)

Metabolic Disease (77)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Free Fatty Acid Receptor Fatty Acid Synthase (FASN) LXR FATP FABP FAAH Amino Acid Derivatives Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111914A

Ferroheme

Others Metabolic Disease

Ferroheme, a complex of ferrous iron and a porphyrin, is an isosteric inhibitor of fatty acid binding to rat liver fatty acid binding protein .

Ferroheme	Others	Metabolic Disease
Ferroheme, a complex of ferrous iron and a porphyrin, is an isosteric inhibitor of fatty acid binding to rat liver fatty acid binding protein .

HY-B0747

Eicosapentaenoic acid ethyl ester EPA ethyl ester; Ethyl eicosapentaenoate; AMR101	Endogenous Metabolite	Metabolic Disease
Eicosapentaenoic acid ethyl ester (EPA ethyl ester) is an orally active ω-3 fatty acid agent. Eicosapentaenoic acid ethyl ester could improve the activity of liver β-oxidase in vitro, reduce the level of liver total triglyceride, increase the content of liver triglyceride and phospholipid ω-3 fatty acid, and increase the total ω-3 fatty acid level in rats .

HY-112829

Denifanstat 1 Publications Verification TVB-2640; FASN-IN-2; ASC-40	Fatty Acid Synthase (FASN)	Metabolic Disease Cancer
Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC₅₀ of 0.052 μM and an EC₅₀ of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research .

HY-108571

CP-775146	PPAR	Metabolic Disease
CP-775146 is a selective PPARα agonist that binds strongly to the PPARα ligand. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway .

HY-153476

GIP/GLP-1 dual receptor agonist-1	GCGR	Metabolic Disease
GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .

HY-142159

FXR/TGR5 agonist 1	FXR G protein-coupled Bile Acid Receptor 1	Metabolic Disease
FXR/TGR5 agonist 1 has agonist action on FXR and TGR5, and can be used for the research of fatty liver disease.

HY-160004

PXL770

AMPK Others

PXL770 is a direct AMP kinase activator. PXL770 can be used in the research of non-alcoholic fatty liver disease (NAFLD) .

PXL770	AMPK	Others
PXL770 is a direct AMP kinase activator. PXL770 can be used in the research of non-alcoholic fatty liver disease (NAFLD) .

HY-N9921

Antcin A	Pyroptosis NOD-like Receptor (NLR)	Inflammation/Immunology
Antcin A is a potent NLRP3 inhibitor that inhibits the assembly and activation of the NLRP3 inflammasome. Antcin A can inhibit Kupffer cell pyroptosis and has liver protective activity. Antcin A can be used to study inflammation, such as non-alcoholic fatty liver disease .

HY-108022A

Azemiglitazone potassium MSDC-0602K	Insulin Receptor PPAR	Metabolic Disease
Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC₅₀ of 18.25 μM . Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance . Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide .

HY-W013215

Adrenic acid cis-7,10,13,16-Docosatetraenoic acid	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Adrenic Acid (cis-7,10,13,16-Docosatetraenoic acid) is a naturally polyunsaturated fatty acid in the adrenal gland, brain, kidney, and vasculature. Adrenic Acid can regulate the vascular tone in arteries of the adrenal cortex. Adrenic Acid also is an inflammation enhancer in non-alcoholic fatty liver disease .

HY-W104819

4-Hydroxyphenylglyoxylate 4-Hydroxyphenylglyoxylic acid; 4-HPGA	Others	Metabolic Disease
4-Hydroxyphenylglyoxylate (4-Hydroxyphenylglyoxylic acid) is an inhibitor of carnitine palmitoyltransferase I (CPT I). 4-Hydroxyphenylglyoxylate can be used to study sensitivity changes in CPT I of liver mitochondria and fatty acid oxidation by isolated hepatocytes. 4-Hydroxyphenylglyoxylate can inhibits fatty acid oxidation .

HY-W018392

Mono-(2-ethylhexyl) phthalate 5+ Cited Publications MEHP; Phthalic acid mono-2-ethylhexyl ester	Endogenous Metabolite	Metabolic Disease
Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

HY-137996

Dehydrovomifoliol	Akt mTOR	Metabolic Disease
Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .

HY-111179

ML261	Others	Inflammation/Immunology
ML261 is a hepatic lipid droplets formation inhibitor with an IC₅₀ value of 69.7 nM. ML261 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and inflammation .

HY-148795

Ritivixibat	Apical Sodium-Dependent Bile Acid Transporter	Cardiovascular Disease Metabolic Disease
Ritivixibat is an inhibitor of ileal bile acid transporter (IBAT), as well as a bile acid modulator. Ritivixibat can be used for research of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases .

HY-19796

Icomidocholic acid 1 Publications Verification Aramchol; C20-FABAC
Icomidocholic acid (Aramchol) is a conjugate of cholic acid and arachidic acid that could inhibit stearoyl coenzyme A desaturase 1 (SCD1) activity. Icomidocholic acid has potential use in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) treatment .

HY-N0723

Neomangiferin	Others	Metabolic Disease
Neomangiferin is a natural C-glucosyl xanthone isolated from m the dried rhizome of Anemarrhena asphodeloides. Neomangiferin has significant therapeutic effects on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in rats .

HY-153815

GLP-1 receptor agonist 11	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 11 (compound 3) is an agonist of GLP Receptor. GLP-1 receptor agonist 11 can be used in the study of diseases such as diabetes and non-alc. fatty liver disease .

HY-126967A

1-Palmitoyl-sn-glycerol 3-phosphate 1-P-GPA	Others	Metabolic Disease
1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate can be used for the research of non‐alcoholic fatty liver disease .

HY-W337335

1-Palmitoyl-sn-glycerol 3-phosphate sodium salt 1-P-GPA sodium salt	Endogenous Metabolite	Metabolic Disease
1-Palmitoyl-sn-glycerol 3-phosphate (sodium salt) (1-P-GPA (sodium salt)) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate (sodium salt) can be used in the study of non-alcoholic fatty liver disease .

HY-N2078

Yamogenin Neodiosgenin	LXR	Metabolic Disease
Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin (Neodiosgenin) inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes .

HY-15259A

CP-640186 hydrochloride Maximum Cited Publications 7 Publications Verification	Acetyl-CoA Carboxylase	Metabolic Disease
CP-640186 hydrochloride is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC₅₀s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 hydrochloride can also stimulate muscle fatty acid oxidation .

HY-15259

CP-640186 Maximum Cited Publications 7 Publications Verification	Acetyl-CoA Carboxylase	Metabolic Disease
CP-640186 is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC₅₀s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 can also stimulate muscle fatty acid oxidation .

HY-116444A

16-HETE	Na+/K+ ATPase	Cardiovascular Disease Inflammation/Immunology
16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease .

HY-163240

HSD17B13-IN-24	17β-HSD	Metabolic Disease
HSD17B13-IN-24 (41) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-161227

HSD17B13-IN-43	17β-HSD	Metabolic Disease
HSD17B13-IN-43 (11) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-163241

HSD17B13-IN-25	17β-HSD	Metabolic Disease
HSD17B13-IN-25 (43) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-163246

HSD17B13-IN-34	17β-HSD	Metabolic Disease
HSD17B13-IN-34 (75) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-163248

HSD17B13-IN-37	17β-HSD	Metabolic Disease
HSD17B13-IN-37 (78) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-163259

HSD17B13-IN-62	17β-HSD	Metabolic Disease
HSD17B13-IN-62 (141) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-161231

HSD17B13-IN-78	17β-HSD	Metabolic Disease
HSD17B13-IN-78 (22) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-163255

HSD17B13-IN-58	17β-HSD	Metabolic Disease
HSD17B13-IN-58 (96) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-162216

HSD17B13-IN-89	17β-HSD	Metabolic Disease
HSD17B13-IN-89 (206) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-162212

HSD17B13-IN-85	17β-HSD	Metabolic Disease
HSD17B13-IN-85 (186) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-162211

HSD17B13-IN-84	17β-HSD	Metabolic Disease
HSD17B13-IN-84 (182) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-162214

HSD17B13-IN-90	17β-HSD	Metabolic Disease
HSD17B13-IN-90 (4) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-162223

HSD17B13-IN-97	17β-HSD	Metabolic Disease
HSD17B13-IN-97 (compound 4) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor with an IC₅₀ value of ≤0.1 µM. HSD17B13-IN-97 has the potential for the research of Nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH) or or drug induced liver injury (DILI) .

HY-N0592

Demethyleneberberine	NF-κB AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
Demethyleneberberine is a natural mitochondria-targeted antioxidant. Demethyleneberberine alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine could serve as a AMPK activator for treating non-alcoholic fatty liver disease (NAFLD) .

HY-133707

β-Muricholic acid	Endogenous Metabolite	Metabolic Disease
β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .

HY-N0592A

Demethyleneberberine chloride	NF-κB AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
Demethyleneberberine chloride is a natural mitochondria-targeted antioxidant. Demethyleneberberine chloride alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine chloride could serve as a AMPK activator for researching non-alcoholic fatty liver disease (NAFLD) .

HY-162221

HSD17B13-IN-95	17β-HSD	Metabolic Disease
HSD17B13-IN-95 (1) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC₅₀ value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease .

HY-162222

HSD17B13-IN-96	17β-HSD	Metabolic Disease
HSD17B13-IN-96 (3) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC₅₀ value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease .

HY-162224

HSD17B13-IN-98	17β-HSD	Metabolic Disease
HSD17B13-IN-98 (5) is an inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), and its IC₅₀ value for estradiol is <0.1 μM. It can be used in the study of nonalcoholic fatty liver disease .

HY-N0401A

(Z)-Ligustilide 2 Publications Verification	Bacterial	Infection Metabolic Disease
(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6 . (Z)-Ligustilide inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer .

HY-W018392S

Mono-(2-ethylhexyl) phthalate-d4 MEHP-d₄; Phthalic acid mono-2-ethylhexyl ester-d₄	Isotope-Labeled Compounds	Metabolic Disease
Mono-(2-ethylhexyl) phthalate-d₄ is a deuterium labeled Mono-(2-ethylhexyl) phthalate (HY-W018392). Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

HY-P99614

Fazpilodemab BFKB8488A	FGFR	Metabolic Disease
Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .

HY-138996

GLP-1 receptor agonist 8	GCGR	Metabolic Disease
GLP-1 receptor agonist 8 is a potent agonist of GLP-1 R. GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17) .

HY-157627

HSD17B13-IN-9	17β-HSD	Metabolic Disease
HSD17B13-IN-9 (252) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of 0.01 μM for 50 nM HSD17B13. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-163259S

HSD17B13-IN-62-d3	17β-HSD	Metabolic Disease
HSD17B13-IN-62-d3 (176) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

HY-163263S

HSD17B13-IN-80-d3	17β-HSD	Metabolic Disease
HSD17B13-IN-80-d3 (179) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research .

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library

2338 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2338 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

HY-L091

Lipid Metabolism Compound Library

650 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 650 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-111914A

Ferroheme	Alkaloids Human Gut Microbiota Metabolites Microorganisms Pyrrole Alkaloids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Others
Ferroheme, a complex of ferrous iron and a porphyrin, is an isosteric inhibitor of fatty acid binding to rat liver fatty acid binding protein .